UniQure

uniQure is a Dutch biopharmaceutical company which makes gene therapies.

Uses your system voice; voice and rate in settings.

≈ 1 min read

Cite, export and learn8 citation formats · 8 exports · lesson and quiz

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

uniQure is a Dutch biopharmaceutical company which makes gene therapies. It has developed several adeno-associated virus gene therapies.

History

In 2012 uniQuire won approval for alipogene tiparvovec (trade name Glybera) for treatment of lipoprotein lipase deficiency. The drug came off the market in 2017 due to limited demand largely blamed on its over US$1 million cost.

In 2022, the US Food and Drug Administration (FDA) granted approval to uniQure's etranacogene dezaparvovec (trade name Hemgenix) for treatment of haemophilia B. The drug was the fifth gene therapy for a rare genetic disease to ever win approval. uniQure partnered with CSL Behring to commercialize Hemgenix. In late 2025, the FDA reversed an earlier decision to grant breakthrough status to uniQure's investigational drug for Huntington's disease, AMT-130.

The FDA's rejection was reversed in June 2026.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1359883966 under CC BY-SA 4.0; modifications have been made.

Provenance

snapshot enwiki-001359883966 · captured 2026-06-17 · ledger · version history

Cite this page as: encyclopegia.org, “UniQure”, snapshot enwiki-001359883966. https://encyclopegia.org/a/uniqure

Sources cited in this revision

8 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.